Tamburino C, Bleiziffer S, Thiele H, et al. - Since there exist few randomized trials comparing bioprostheses for transcatheter aortic valve replacement (TAVR), and no trials have compared TAVR bioprostheses with supra-annular design, therefore, researchers compared the clinical results of the ACURATE neo and CoreValve Evolut valves in this randomized trial, named as the SCOPE 2 trial. Participants were patients ≥ 75 years with an indication for transfemoral TAVR. The participants were randomized to receive either the ACURATE neo (n = 398) or the CoreValve Evolut bioprostheses (n = 398). Findings revealed that non-inferiority in terms of all-cause death or stroke at 1 year was not met by transfemoral TAVR with the self-expanding ACURATE neo when compared with the self-expanding CoreValve Evolut. A lower incidence of new permanent pacemaker implantation was reported in relation to transfemoral TAVR with self-expanding ACURATE neo. In secondary analyses, the ACURATE neo was found to be related to more moderate or severe aortic regurgitation at 30 days as well as cardiac death at 30 days and 1 year.